ArticleScientific reports2025
Therapeutic comparison of MitoTEMPO and rosmarinic acid as mitochondria targeted and non targeted antioxidants evaluated in rat sciatic nerve crush injury model.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Epilepsy-induced heart damage and sudep risk: ion channelopathies, calcium homeostasis, and the therapeutic potential of resveratrol.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Protective Role of Hesperidin Against Deltamethrin-Induced Cardiovascular Structural Damage: Involvement of Caspase-3-Driven Apoptosis and Fibrosis Suppression in Rats.Journal of cardiovascular development and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondria are key organelles involved in various pathophysiological processes. As the primary site of reactive oxygen species (ROS) production, they represent a major target for many therapeutic agents. In this study, the therapeutic effects of a mitochondria-targeted antioxidant (MitoTEMPO, MT) and a conventional yet potent antioxidant compound (rosmarinic acid, RA) were compared in a rat model of sciatic nerve crush injury, focusing on nerve conduction parameters and histological structures. A total of 28 adult Wistar Albino rats were used in the study, with seven animals assigned to each group: SHAM, crush injury (CI), RA, and MT. The CI model was induced by applying a mosquito-type clamp to the sciatic nerve for 40 s. Nerve conduction parameters were evaluated using compound action potentials (CAPs) analyzed through comprehensive mathematical methods. In addition, structural alterations were assessed via histological staining and scoring. Both RA and MT treatments exerted therapeutic effects on the CAP parameters, which were progressively suppressed by CI. However, the efficacy of MT was more pronounced-particularly in nerve fibers with conduction velocities between 65 and 69 m/s, where significant improvements were observed. Histological evaluation of CI group preparations revealed neuronal loss between nerve fascicles, axonal degeneration, increased collagen deposition, cytoplasmic vacuolization, and myelin sheath degeneration. MT treatment was more effective than RA in alleviating these pathological alterations. In conclusion, this study underscores the importance of mitochondria-targeted antioxidant strategies in reversing electrophysiological suppression and structural damage following peripheral nerve injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.